ALN-CIDEB

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Liver DiseaseMetabolic Dysfunction-Associated Steatotic Liver Disease

221 competitors in Liver Disease

#DrugCompanyPhaseTrials

1

Mounjaro

Eli Lilly

Phase 3

—2

Neurontin

VViatris Specialty LLC

Phase 3

13

Viagra

VViatris Specialty LLC

Phase 3

14

Inderal

WWyeth-Lederle Vaccines

Phase 3

15

Sandostatin

Sun Pharma

Phase 3

16

Neupogen

EEastern Cooperative Oncology Group

Phase 3

—7

Promacta

GSK

Phase 2

38

Retatrutide

Eli Lilly

Phase 3

—9

Ozempic

Novo Nordisk

Phase 2

110

Jardiance

Boehringer Ingelheim

Phase 2

2Show 34 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Recruiting·Regeneron·Preclinical·NCT06836609·132 enrolled

Details

Drug Info

Related News